Merrimack Pharmaceuticals Inc.

297 articles about Merrimack Pharmaceuticals Inc.

• Merrimack Reports Third Quarter 2023 Financial Results

  11/2/2023

  Merrimack Pharmaceuticals, Inc. announced its third quarter 2023 financial results for the period ended September 30, 2023.

• Merrimack Reports Second Quarter 2023 Financial Results

  8/3/2023

  Merrimack Pharmaceuticals, Inc. announced its second quarter 2023 financial results for the period ended June 30, 2023.

•  Merrimack Reports First Quarter 2023 Financial Results

  5/4/2023

  Merrimack Pharmaceuticals, Inc. announced its first quarter 2023 financial results for the period ended March 31, 2023.

• Merrimack Reports Full Year 2022 Financial Results

  3/9/2023

  Merrimack Pharmaceuticals, Inc. announced its full year 2022 financial results for the period ended December 31, 2022.

• Merrimack Provides Ipsen Report That Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

  11/9/2022

  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] announced that Ipsen, SA (“Ipsen”) issued a press release today reporting its primary analysis of the results of its Phase III NAPOLI 3 trial of Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) as a treatment of first line metastatic pancreatic ductal adenocarcinoma (mPDAC). 

• Merrimack Reports Third Quarter 2022 Financial Results

  11/3/2022

  Merrimack Pharmaceuticals, Inc. announced its third quarter 2022 financial results for the period ended September 30, 2022.

• Merrimack Reports Second Quarter 2022 Financial Results

  8/4/2022

  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its second quarter 2022 financial results for the period ended June 30, 2022.

• Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer

  8/3/2022

  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] announced that Ipsen, SA (“Ipsen”) has issued a press release today reporting its primary analysis of the results of its Phase 3 trial of Onivyde® (irinotecan liposomal injection) as a treatment of second line small cell lung cancer (SCLC).

• Merrimack Reports First Quarter 2022 Financial Results

  5/5/2022

  Merrimack Pharmaceuticals, Inc. announced its first quarter 2022 financial results for the period ended March 31, 2022.

• Merrimack Reports Full Year 2021 Financial Results

  3/9/2022

  Merrimack Pharmaceuticals, Inc. announced its full year 2021 financial results for the period ended December 31, 2021.

• Merrimack Reports Third Quarter 2021 Financial Results

  11/4/2021

  Merrimack Pharmaceuticals, Inc. today announced its third quarter 2021 financial results for the period ended September 30, 2021.

• Merrimack Reports Second Quarter 2021 Financial Results

  8/5/2021

  Merrimack Pharmaceuticals, Inc. announced its second quarter 2021 financial results for the period ended June 30, 2021.

• Merrimack Reports Full Year 2020 Financial Results

  3/10/2021

  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2020 financial results for the period ended December 31, 2020.

• Merrimack Reports Third Quarter 2020 Financial Results

  11/5/2020

  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its third quarter 2020 financial results for the period ended September 30, 2020. “We are pleased that both Ipsen Pharmaceuticals and Elevation Oncology continue to enroll patients in separate clinical stage programs which could result in milestone payments to Merrimack,” said Gary Crocker, Chairman of Merrimack’s Board of

• Merrimack Reports Second Quarter 2020 Financial Results

  8/7/2020

  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its second quarter 2020 financial results for the period ended June 30, 2020. “We are pleased by recent news releases from both Ipsen Pharmaceuticals and Elevation Oncology, which are conducting separate programs which could result in milestone payments to Merrimack. Ipsen announced receipt of Fast Track designation from th

• Merrimack Reports First Quarter 2020 Financial Results

  5/7/2020

  Merrimack Pharmaceuticals, Inc. announced its first quarter 2020 financial results for the period ended March 31, 2020.

• Merrimack Divests Early Stage Asset for $2.25 Million; Provides Strategy Update

  4/2/2020

  Merrimack Pharmaceuticals, Inc. announced receipt of $2.25 million in connection with the closing of a transaction in which the Company sold certain assets related to its preclinical nanoliposome programs to Celator Pharmaceuticals, Inc.

• Merrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special Dividend

  12/3/2019

  As a result of this milestone payment, Merrimack’s Board of Directors has authorized and declared a special cash dividend of $6.7 million on the Company’s common stock

• Merrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights Plan

  12/3/2019

  The Plan is designed to protect the Company’s ability to use its valuable net operating loss carryforwards and certain other valuable tax attributes.

• JFL Capital Ends Campaign at Merrimack

  9/24/2019

  JFL Capital Management, LLC (together with its affiliates, "JFL Capital"), the largest stockholder of Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") (NASDAQ: MACK), with ownership of approximately 9.4% of the Company's outstanding shares, announced today that it has withdrawn its solicitation in connection with the Company's 2019 annual meeting of stockholders (the "Annual Meeting").